Update of Treatment for Children of tuberous sclerosis complex

Authors

  • Fuyong Jiao Childrens Hospital Shaanxi Provincial People’s Hospital, Xi’an Jiao tong University, Xi’an China
  • Li Wei Childrens Hospital Shaanxi Provincial People’s Hospital, Xi’an Jiao tong University, Xi’an China
  • Bilal Hiader Shamsi Department of pediatrics, Shenmu County Hospital Shaanxi Province, China

Abstract

The children of tuberous sclerosis complex were also named Bourneville disease, and its neural symptoms and pathological change was firstly described by Bourneville in 1908. Heinrich Vogt pointed out the three main symptoms, namely epilepsy, mental retardation and facial angiofibromas. It is an autosomal dominant disease. It is an important cause of epilepsy, autism, and renal and pulmonary disease in children and adults. The appropriate therapy and prognosis for TSC patients are often different than that for individuals with epilepsy, renal tumors, or interstitial lung disease from other causes. In recent years, certain progress have been made in management of tuberous sclerosis, inhibitors of the mammalian target of rapamycin (mTOR) have demonstrated regression of astrocytomas, angiofibromas, and angiomyoliomas, as well as improved pulmonary function in persons with TSC. This article reviews the current therapeutic recommendations for medical and surgical management of neurologic, renal, and pulmonary manifestations of TSC

Keywords:

Children of tuberous sclerosis complex, Treatment, Progress

Downloads

Download data is not yet available.

Published

05-04-2015
Statistics
44 Views | 26 Downloads

How to Cite

Jiao, F., L. Wei, and B. H. Shamsi. “Update of Treatment for Children of Tuberous Sclerosis Complex”. Journal of Innovations in Pharmaceutical and Biological Sciences, vol. 2, no. 2, Apr. 2015, pp. 152-8, https://jipbs.com/index.php/journal/article/view/55.

Issue

Section

Review Article